Effect of Zirconium oxide nanoparticle on serum level of testosterone and spermatogenesis in the rat: An experimental study

Abstract Background Zirconium nanoparticles are used as health agents, pharmaceutical carriers, and in dental and orthopedic implants. Objective This studyaimed to investigate the effects of Zirconium oxide nanoparticles on the process of spermatogenesis in rat. Materials and Methods In this experimental study, 32 male Wistar rats (150-200 gr), with range of age 2.5 to 3 months were used and divided into four groups of eight per each. The control group received 0.5 ml of distilled water and the three experimental groups received 50, 200, and 400 ppm doses of Zirconium oxide nanoparticles solution over a 30-day period, respectively. At the end of the experiment, tissue sections were taken from the testis and stained with hematoxylin-eosin. Serum concentration of testosterone was measured by enzyme-linked immunosorbent assay. Results In the experimental group receiving 400 ppm Zirconium oxide nanoparticles, the number of Spermatogonia cells (p ≤ 0.01), Spermatocytes (p ≤ 0.01), Spermatids (p ≤ 0.001), and sertoli and Leydig cells (p ≤ 0.05) showed a significant decrease compared to the control group. Serum testosterone concentration did not change significantly in all experimental groups receiving Zirconium oxide nanoparticles compared to the control group. Experimental group received 400 ppm Zirconium oxide nanoparticles shrinkage of seminal tubules and reduced lumen space compared to control group. Conclusion Zirconium oxide nanoparticles are likely to damage the testes by increasing Reactive oxygen species production and free radicals.


Introduction
Nanotechnology refers to the technology of materials that measure about 1-100 nanometers (1). The nanoparticles have unique physical and chemical properties that cannot be seen even in the materials from which they are derived.
The small size and high surface area of the nanoparticles increase their chemical activity and allow them to act as a high performance catalyst (2).
Since 1960, Zirconium nanoparticles have been introduced as biomaterials for use in orthopedics in the form of artificial joints and in dentistry as coatings, implants, and composites (3). Zirconium oxide ceramic nanostructures have also been widely used in drug transducers as drug carriers for several drugs such as Myconazol, Pennyceline, Alendronit, and Zolendronitthat (4,5). Zirconium nanoparticles have been shown to cause significant DNA damage (6) and mesenchymal stem cell death (7) and inhibit cell proliferation in rodent fibroblast cell lineages (8).
While a study by Demir and co-worker showed that Zirconium oxide nanoparticles lead to gene toxicity in peripheral blood lymphocytes and cultured renal embryonic cells (9), a study by Ye and co-worker found that high concentrations of Zirconium oxide nanoparticles induce cell death and morphological changes in cultured 3T3-E1 cells. In addition, zirconium oxide nanoparticles induced osteogenic differentiation (10). A study by Gad and co-worker showed that Zirconium oxide nanoparticles have antifungal activity against Candida albicans (11).
Moreover, in a study by Banerjee and co-worker, it was found that Zirconium oxide nanoparticles have antimicrobial activity (12), and Atalay and co-worker in 2018 reported that Zirconium oxide nanoparticles induce DNA damage and cell death in L929 mouse fibroblast cell liners (13). While Arefian and co-worker reported in their study that Zirconium oxide nanoparticles had strong toxic effects on liver and kidney factors (14) Omidi and co-worker showed that zirconium oxide nanoparticles at a dose of 400 ppm resulted in a significant decrease in Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), and testosterone in female rats (15).

Animal treatment
The animals were divided into four groups of eight animals.

Histological tests
After the animals were sacrificed, their left testicles were removed. At the fixation stage, the tissues were fixed in 10% buffered formalin. The

Ethical consideration
All experiments were conducted according to the protocol provided by the ethics committee of Islamic Azad University Arsanjan Branch (IR.IAU.A.REC.1397.001).

Statistical analysis
Data were analyzed using the Statistical Package for the Social Sciences (SPSS software, Chicago, Illinois), version 18.0., analysis of variance (ANOVA) and Tukey Test. Statistical inference boundary was statistically significant for the experimental groups receiving different amounts of zirconium oxide nanoparticles at P ≤ 0.05 level compared to the control group. In this study, the results of experiments performed along with the relevant statistical calculations are presented in the form of graphs.

Results
While the mean body weights in the experimental groups (I) and (II) did not change significantly compared to control group, the mean body weight in the experimental group (III) significantly decreased compared to the control group (p ≤ 0.05, Figure 3).
The mean testicular weight in all experimental groups receiving different amounts of zirconium oxide nanoparticles did not change significantly compared to the control group ( Figure 4).
Interestingly, while the average number of spermatogonial cells in the experimental groups (I) and (II) did not change significantly compared to the control group, the average number of spermatogonial cells in the experimental group (III) decreased significantly compared to the control group (p ≤ 0.01) ( Figure 5).
Further, although the average number of spermatocyte cells in the experimental groups (I) and (II) did not change significantly compared to the control group, the average number of spermatocyte cells in the experimental group (III) decreased significantly compared to the control group (p ≤ 0.01) ( Figure 5).
However, the average number of spermatid cells in all experimental groups (I), (II) and (III) significantly decreased compared to the control group (p ≤ 0.0001, respectively) ( Figure 6).
As for the Leydig cells, the average number of Leydig cells in the experimental groups (I) and (II) did not change significantly compared to the control group. However, the average number of Leydig cells in experimental group (III) decreased significantly compared to the control group (p ≤ 0.05, Figure 7).
Further, the average number of Sertoli cells in the experimental groups (I) and (II) also did not change significantly compared to the control group. However, the average number of Sertoli cells in the experimental group (III) decreased significantly compared to the control group (p ≤ 0.05, Figure 7).
The mean serum testosterone concentration in all experimental groups receiving different amounts of zirconium oxide nanoparticles did not change significantly compared to the control group (Figure 8).

Results of testicular tissue studies
There were no pathological changes in testicular photomicrographs of the control group and testicular tubules, and germ cells appeared normal ( Figure 9).
In the experimental group (I), recipients of zirconium oxide nanoparticles (50 ppm) showed a decrease in the density of different types of germ cells compared to the control group ( Figure 10).
In the experimental group (II), recipients of zirconium oxide nanoparticles (200 ppm) showed better shrinkage of seminiferous tubules and decreased number of germ cells, especially spermatid cells, compared to the control group ( Figure 11).
In the experimental group (III) showed a sharp decrease in the number of seminiferous tubules. The irregularity and disruption of the germinal epithelium and shrinkage of the tubules were visible. In addition, Spermatogonia, Spermatocytes, Spermatids, Sertoli and Leydig cells were noticeable in the lumen. Therefore, tissue degradation is clearly observed in this experimental group (Figure 12).
In the experimental groups receiving different amounts of Zirconium oxide nanoparticles, the number of spermatogonia, primary spermatocytes, and spermatids decreased compared to the control group. These effects are dose dependent and in the receiving group the maximum amount of Zirconium oxide nanoparticles (400 ppm) is higher than the other experimental groups.

International Journal of Reproductive BioMedicine
Mehdikhani et al.

Discussion
The mean body weight in the experimental group receiving 400 ppm zirconium oxide nanoparticles decreased significantly compared to the control group (p ≤ 0.05). These results are in line with a 2010 study by Kim and co-worker, where it was shown that the administration of 500 mg/kg of silver nanoparticles orally for 13 weeks in male mice resulted in lower body weight and increased blood cholesterol levels (20).
The mean testicular weight in all experimental groups receiving different amounts of zirconium oxide nanoparticles did not change significantly compared to the control group. A study by Fan and co-worker showed that exposure to mice with silicon oxide nanoparticles resulted in a significant decrease in testicular weight. Silicon oxide nanoparticles are likely to reduce the testicular weight of rat by oxidative damage to the testes by increasing ROS (reactive oxygen species) (21).
The average number of Sertoli cells in the experimental group receiving 400 ppm zirconium oxide nanoparticles decreased significantly compared to the control group (p ≤ 0.05). A 2013 study by Talebi and co-worker showed that zinc oxide nanoparticles damage Sertoli cells. The mechanism of the effects of nanoparticles on the testes of mice is not known. Zinc oxide nanoparticles are likely to have deleterious effects on Sertoli cell function through the formation of multinuclear giant cells, increasing vacuoles in Sertoli cells. The results of this study were consistent with the results of the study (22). Also, Braydich-Stolle and co-worker showed that silver nanoparticles decrease ATP levels in Sertoli cells by reducing FYN/Kinase enzyme levels in Sertoli cells. Silver nanoparticles appear to damage the Sertoli cells and the germ cells by reducing the amount of FYN/Kinase enzyme followed by ATP depletion. Silver nanoparticles can disrupt Sertoli cell damage by inhibiting Glial cell-derived neurotrophic factor (GDNF) signaling pathway, which is secreted from Sertoli cells, resulting in a proliferation of spermatogonial cells (23).
Further, the average number of Leydig cells in the experimental group receiving 400 ppm zirconium oxide nanoparticles decreased significantly compared to the control group (p ≤ 0.05). These results are consistent with the study of Talebi and co-worker (22). The results in their study showed that silver nanoparticles can affect Leydig cells and testosterone inhibitor synapses, and the number of Leydig cells was significantly reduced in the groups treated with silver nanoparticles (20).
Omidi and co-worker investigated the effect of zirconium nanoparticles on testosterone, LH, and FSH in female rat. Zirconium nanoparticles led to a significant decrease in plasma levels of testosterone in female rat (15). Testosterone is higher in the male than in the female. In a recent study, the dose of zirconium oxide nanoparticles used was not sufficient to influence testosterone levels in male rats. Therefore, in all groups the level of testosterone decreased but this decrease was not significant (p ≤ 0.05).
Jia and co-worker reported that titanium dioxide nanoparticles significantly reduced serum testosterone levels and expression in rat testes. Titanium dioxide nanoparticles decreased the expression of 17 beta-hydroxy steroids dehydrogenase and P 450 17 alphahydroxysteroid dehydrogenase and increased the expression of cytochrome P 450-19 (key enzyme for translating testosterone to estradiol) in mice. Titanium dioxide nanoparticles at the translational level cause changes in testosterone. In addition, titanium dioxide nanoparticles may reduce spermatogenesis by reducing serum testosterone synthesis (24). Due to similarities in zirconium and titanium nanoparticles in their properties, a decrease in serum testosterone level was observed in male rats treated with zirconium nanoparticle oxide, but this decrease was not significant.
Other researchers have shown that nanoparticles lead to the decline of germ cells. Miresmaeili et al. reported that silver nanoparticles led to a significant decrease in the number of spermatogonia, primary spermatocytes, spermatids, and spermatozoa (25).
Lan and Yang showed that nanoparticles are capable of crossing the blood-testicular barrier, thereby exerting inflammatory effects on testicular tissue. The nanoparticles do not directly destroy the nucleus membrane. Nanoparticles first affect the cytoskeleton. They then destroy the nucleus membrane. In addition, the nanoparticles may be endocytosed by sex cells or Leydig cells, causing changes in inflammation in the cell and then exocytosis (16).
Cellular and tissue damage can be caused by the extensive production of ROS in inflammatory diseases (26). In addition, increasing ROS production can lead to increased production of external cytokines and further damage (27).
Various studies have shown that zirconium nanoparticles can lead to increased production of ROS and increased caspase-3, mitochondrial membrane potential, and DNA strand breaks. Zirconium nanoparticles can cause cellular toxicity by causing mitochondrial damage (28,13).
Studies have shown that exposure to zirconium oxide nanoparticles resulted in a significant decrease in Glutathione peroxidase (GPx) in rat. In fact, the imbalance between the production of free radicals and their ability to detoxify by GPx in the molecular mechanism of toxicity causes cell damage (29,30,31). Concerning the results, it seems that irconium oxide nanoparticles decrease spermatogenesis through the mechanisms described. It is also possible that zirconium oxide nanoparticles may decrease spermatogenesis by reducing serum testosterone synthesis.

Conclusion
Studies have shown that zirconium oxide nanoparticles can damage testicular tissue, which is dose-dependent. In addition, the doses of zirconium oxide nanoparticles in this study did not lead to a significant change in the serum concentration of testosterone.